IL-2 + anti-CD3/28 mAbs, or IL-2 + sAJ2 or IL-2 + anti-PD1-treated ALS patients’ PBMCs secreted significantly increased IFN-γ compared to PBMCs of healthy individuals with the same treatments (Figure 1e–h and Figure S2a,b). Here, IL2 is linked to amyotrophic lateral sclerosis.